arrow
孙

孙会 (Hui-Chuan Sun)

Zhongshan Hospital Fudan University
H指数:74
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial

局部晚期肝细胞癌在阿替利珠单抗和贝伐珠单抗治疗后行肝切除术与维持治疗的比较(TALENTOP研究):一项多中心、开放标签、随机、III期临床试验

2026-08-200
PRE
Spatiotemporal multiomics uncover tumor ecosystem dynamics during metastatic colonization

时空多组学揭示转移定植期间的肿瘤生态系统动态

Science
IF45.8
2026-07-300
PRE
Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial

中国患者术后肝内胆管癌的辅助性卡瑞利珠单抗联合卡培他滨治疗(ACC):一项单臂、单中心、开放标签、II期临床试验

2025-11-270
PRE
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study

替雷利珠单抗联合仑伐替尼和GEMOX方案治疗不可切除的局部晚期胆道癌的转化治疗(ZSAB-TransGOLP):一项多中心、前瞻性、Ⅱ期研究

2025-08-290
PRE
First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study

一线tislelizumab和ociperlimab联合吉西他滨和顺铂治疗晚期胆道癌 (zsab-top): 一项多中心,单臂,2期研究

2025-08-210
OAAI
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment

《柳叶刀》关于应对全球肝细胞癌负担的委员会报告:从预防到治疗的综合策略

2025-07-280
PRE